Cost effectiveness of a novel SwaRSA Strategy to reduce acute exacerbations of COPD
Published in Neuroscience, Protocols & Methods, and General & Internal Medicine
The paper discusses the significant economic burden of Chronic Obstructive Pulmonary Disease (COPD) and the potential cost savings from reducing COPD exacerbations. A decision analytic model that evaluates the cost-effectiveness of a Swallowing and Respiratory Sensation Assessment (SwaRSA) strategy, involving swallowing and respiratory sensation assessment tests and subsequent swallowing rehabilitation, is presented to reduce COPD exacerbations. The model suggests that self-assessment with the Eating Assessment Tool (EAT-10) and subsequent intervention is a highly cost-effective option compared to no-SwaRSA.
Key Points: Novel SwaRSA Decision Analytic Model; Epiu I. et al 2025 https://pubmed.ncbi.nlm.nih.gov/40200355/
Economic Burden of COPD
- COPD represents a considerable economic burden globally, with an estimated cost of US$ 2.1 trillion.
- Annual COPD costs in the USA are expected to increase to 40 billion USD per year.
- Australia spent about AUD$ 831.6 million in 2020-21 on the management of COPD, with over half of this cost for hospital care.
Potential for Cost Savings
- A significant portion of the COPD management cost could be avoided by reducing exacerbations.
Cost-Effectiveness of SwaRSA Strategy
- The decision analytic model assessed the cost-effectiveness of a Swallowing and Respiratory Sensation Assessment (SwaRSA) strategy, which involved swallowing and respiratory sensation assessment tests and subsequent swallowing rehabilitation.
- Three individual testing strategies within the SwaRSA approach were found to be cost-effective, with incremental cost-effectiveness ratios per QALY ranging from $27,000 to $37,000 AUD.
- The EAT-10 and the tongue strength were the two dominant options on the cost-effectiveness frontier.
- The model results were robust to variations in one-way and probabilistic sensitivity analyses, and the self-assessment with the EAT-10 and subsequent intervention was highly cost-effective relative to no-SwaRSA.
Here are the key implications of the findings for healthcare policy regarding COPD management:
-
The high economic burden of COPD, estimated at over $2 trillion globally and $40 billion annually in the US, highlights the need for more effective and cost-efficient management strategies.
-
Novel finding that a significant portion of COPD costs could be avoided by reducing exacerbations suggests that interventions targeting exacerbation prevention should be a priority for policymakers.
-
The high prevalence of swallowing difficulties (dysphagia) among COPD patients, affecting up to 56% of hospitalized patients, suggests that screening and management of swallowing disorders should be integrated into standard COPD care.
-
This cost-effectiveness analysis of the SwaRSA strategy, which includes swallowing and respiratory sensation assessment tests followed by swallowing rehabilitation, provides strong evidence that such an approach can be a highly cost-effective way to reduce COPD exacerbations and associated costs.
-
Further research may be needed to validate these findings in different healthcare settings and populations, but the current evidence suggests that integrating swallowing assessment and rehabilitation into COPD management should be a priority for healthcare policy
Follow the Topic
-
BMC Pulmonary Medicine
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Technological advancements in diagnosis of pulmonary disease
BMC Pulmonary Medicine is calling for submissions to our Collection on technological advancements in the diagnosis of pulmonary disease.
The landscape of interventional pulmonary medicine is evolving rapidly, propelled by innovative technologies aimed at enhancing the minimally invasive diagnosis and treatment of lung diseases. Advances in medical technology, such as artificial intelligence, machine learning, and novel imaging techniques, are providing clinicians with unprecedented tools for diagnosing cancers and other diseases of the chest and mediastinum as well as chronic obstructive pulmonary disease (COPD) and asthma. This Collection seeks to explore the latest minimally invasive endoscopic diagnostic and therapeutic innovations that are reshaping our understanding of pulmonary diseases, thereby improving patient outcomes and fostering personalized treatment strategies.
Recent advancements, such as the development of novel disease biomarkers and enhanced diagnostic and therapeutic tools, have the potential to revolutionize clinical practices. This could lead to earlier interventions and better outcomes, and by integrating new methods and technologies, healthcare providers can improve early detection, diagnostic accuracy and efficiency, and therapies ultimately leading to better management of lung diseases and improved quality of life for patients.
Potential research topics can include but are not limited to:
- Diagnostic innovations in pulmonary disease
- New technologies in lung disease diagnosis
- Novel disease biomarkers for pulmonary conditions
- Advancements in diagnostic and disease monitoring techniques
- Horizon scanning for future diagnostic tools
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
This Collection supports research aligned with SDG 3: Good Health and Well-Being and SDG 9: Industry, Innovation and Infrastructure.
Publishing Model: Open Access
Deadline: May 21, 2027
Pediatric pulmonary disease and disorders
BMC Pulmonary Medicine is calling for submissions to our Collection on pediatric pulmonary diseases and disorders. Pediatric pulmonary diseases and disorders encompass a diverse range of conditions affecting the respiratory health of children, including asthma, cystic fibrosis, bronchitis, pulmonary vascular disease, ciliopathies, bronchopulmonary dysplasia, interstitial and diffuse lung diseases of childhood, and pulmonary infections including tuberculosis. These conditions can significantly impact a child's quality of life and overall development, making early diagnosis and effective management critical. The complexities of pediatric pulmonary disorders necessitate a multidisciplinary approach, bringing together pediatricians, pulmonologists, respiratory therapists, and researchers to develop better understanding and treatments.
Advances in the field have led to improved diagnostic techniques, targeted therapies, and a deeper understanding of the pathophysiological mechanisms underlying these conditions. With the rise of personalized medicine and innovative treatment options, the outlook for children suffering from pulmonary disorders continues to improve. Furthermore, research has highlighted the importance of addressing environmental factors, enhancing preventive measures, and fostering family-centered care in managing these conditions effectively.
Future research in pediatric pulmonary disorders may pave the way for groundbreaking treatments, including gene therapy and advanced biologics tailored to the individual needs of pediatric patients. Additionally, as our understanding of the interplay between genetics, environment, and respiratory health grows, we may see the development of novel prevention strategies that can significantly reduce the incidence and impact of these diseases in children.
Potential research topics can include but are not limited to:
- Asthma management in pediatric populations
- Advances in cystic fibrosis therapies
- Understanding bronchopulmonary dysplasia
- Pediatric pneumonia and primary ciliary dyskinesia: trends and treatments
- Pediatric interstitial lung disease
- Tuberculosis in children: challenges and strategies
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jun 09, 2027
